Future of Generics The Falsified Medicines Directive – truly an opportunity for... Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’.
Partner Content Partner Content four weeks to go until Europe’s only Parallel Trade event Parallel Trade conference 2019
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
